Category: Pharmaceutical Industry
-
Abbott wins another UPC PI against glucose sensor rival Sibio
The UPCâs Milan Local Division has granted Abbott a second UPC-wide preliminary injunction in its patent infringement case against Chinese rival Sibio, despite allowing the latterâs late-presented claim construction arguments to be admitted.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent CourtÂ
The Munich I Regional Court has found that Accord infringed TOWAâs dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.
-
Lupin granted win against Vertex in Delaware over cystic fibrosis drug patents
Lupinâs generic version of Vertexâs cystic fibrosis treatment Kalydeco does not infringe the latterâs patents, Judge Stephanos Bibas of the Third Circuit has ruled.
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal âthreatens to upendâ long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgenâs bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
Chinaâs top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. Chinaâs top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
EWHC hinders Accordâs plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accordâs âattacksâ on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendantâs supplementary protection certificate.
-
Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂ
Speakers already confirmed for the event include Hon. Emmanuel Gouge and AleĆĄ Zalar of the UPC, Judge Oliver Schön of the Munich Regional Court, Abbottâs Gael Tisack, Ericssonâs Gabriele Mohsler, Nokiaâs Clemens Heusch, and SIM IPâs Erich Spangenberg.
-
U.S. GLP-1 patent docket grows with raft of new complaints from Eli Lilly, Novo Nordisk
This could well be the start of a wide-ranging, multi-jurisdictional campaign by Eli Lilly to defend its rights around Mounjaro and Zepbound.
-
UPC keeps Merz infringement case despite earlier French filing
The UPCâs Paris LD rejected Viatrisâ attempt to halt Merzâs infringement action in favor of parallel proceedings before a French national court. The ruling clarifies when earlier national proceedings prevent the UPC from continuing with an infringement action.
-
âThe future of medicine and diagnosticsâ: behind the patent enforcement strategy of biotech tools company SeerÂ
Seerâs VP of Legal, George Fox, discusses the challenges that its patent portfolio has recently overcome, and the enforcement campaign it has launched in the U.S.Â